Morgan Stanley (NY:MS)

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Topics Artificial Intelligence

One AI Agent, Two Verdicts: Muse Lifts the Nasdaq to a Record and Knocks the Banks ↗

Today 2:59 EDT

Via Chartmill

Topics Artificial Intelligence

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

Today 0:24 EDT

Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the...

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit ↗

Today 0:02 EDT

LPL Financial, Northern Trust, Ameriprise Financial, Morgan Stanley, and Paymentus Stocks Trade Down, What You Need To Know

Topics Artificial Intelligence

September 22, 2026

What Happened? A number of stocks fell in the afternoon session after investors kept bidding the group lower after last week’s Federal Reserve hike. On Septe...

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,...

Topics Economy

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗

September 22, 2026

There's a strong possibility the defense and aerospace giant's backlog will grow even more in the near future.

Topics Cannabis Government

Great News for RTX Investors (Hint: It Relates to Its Record $289 Billion Backlog) ↗

September 22, 2026

There are no AI data centers without copper.

Freeport-McMoRan's Low-Cost Secret to Take Advantage of Record Copper Prices ↗

September 22, 2026

Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during...

Topics Artificial Intelligence

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum ↗

September 22, 2026

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its...

Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion ↗

September 21, 2026

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services...

Topics Artificial Intelligence

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 ↗

September 21, 2026

Today, Sept. 21, 2026, semiconductor stocks surged on AI demand while Bitcoin topped $87,000, offsetting energy sector weakness.

Topics ETFs Earnings

Stock Market Today, Sept. 21: Tech Strength Powers Nasdaq to Record Close ↗

September 21, 2026

What Happened? Shares of networking chips designer Marvell Technology (NASDAQ: MRVL) jumped 6.1% in the afternoon session after the company announced it will...

Topics Artificial Intelligence Economy Stocks

Marvell Technology (MRVL) Shares Skyrocket, What You Need To Know

September 21, 2026

ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing...

Topics Artificial Intelligence Economy

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand ↗

September 21, 2026

The chipmaker announced plans to unveil next-generation technology at an upcoming tech conference.

Why Marvell Stock Rallied Today ↗

September 21, 2026

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ...

Topics Artificial Intelligence

Moderna (MRNA) Stock Trades Up, Here Is Why

September 21, 2026

A combined Tesla and SpaceX would dominate physical AI applications, according to Morgan Stanley. Both stocks gained on Monday.

Topics Artificial Intelligence

Tesla Opens Roadster Preorders; More SpaceX Merger Talks Surface ↗

September 21, 2026

Via Investor's Business Daily

Topics Artificial Intelligence

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig ↗

September 21, 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of...

Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia...

Ardelyx Targets $500M Revenue This Year, Profitability by 2027 ↗

September 21, 2026

Cognex (NASDAQ:CGNX) Chief Financial Officer Dennis Fehr said the machine-vision company is pursuing growth across logistics, packaging, semiconductors, electronics and data-center supply chains,...

Cognex Touts AI Vision Growth Across Data Centers, Semis and China ↗

September 21, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Topics Artificial Intelligence

1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm

September 21, 2026

NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease...

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference ↗

September 20, 2026

Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference ↗

September 20, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing...

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter,...

Topics Artificial Intelligence

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗

September 20, 2026

Aurora Innovation (NASDAQ:AUR) is preparing to expand its autonomous-trucking operations through a second-generation hardware rollout, a planned transition toward a driver-as-a-service model and...

Aurora Innovation Targets 20 Driverless Trucks a Week as DaaS Shift Takes Shape ↗

September 20, 2026

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B ↗

Topics Artificial Intelligence

September 20, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the...

WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a...

Topics Cannabis

WW International Eyes Cash Flow Turnaround as GLP-1 Care Gains Momentum ↗

September 20, 2026

Stanley Black & Decker (NYSE:SWK) CEO Chris Nelson said the company is progressing against three priorities: strengthening its core brands, improving operational execution and accelerating innovation....

Topics Supply Chain

Stanley Black & Decker Targets Margin Gains as DEWALT Takes Share ↗

September 20, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and...

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets ↗

September 20, 2026

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare...